Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for...
-
Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
-
Company Announcement COPENHAGEN, Denmark; August 15, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,700 shares as a consequence of the exercise of employee warrants. The...
-
August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S....
-
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. ...
-
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with...
-
Company Announcement Net sales of DARZALEX® in the second quarter of 2023 totaled USD 2,431 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
-
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss next stepsData from the clinical...
-
Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer...
-
Company Announcement COPENHAGEN, Denmark; June 20, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,395 shares as a consequence of the exercise of employee warrants. The...